Lupin Limited (BOM:500257)

Market Cap	1.04T +10.1%
Revenue (ttm)	279.58B +23.1%
Net Income	53.33B +62.5%
EPS	116.44 +62.4%
Shares Out	457.22M
PE Ratio	19.55
Forward PE	22.58
Dividend	18.00 (0.80%)
Ex-Dividend Date	Jul 25, 2025

Volume	37,954
Open	2,262.90
Previous Close	2,263.85
Day's Range	2,250.00 - 2,292.10
52-Week Range	1,838.65 - 2,492.00
Beta	0.23
Analysts	Buy
Price Target	2,458.50 (+7.98%)
Earnings Date	May 7, 2026

About Lupin

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, ...

• Industry: Pharmaceutical Preparations
• Founded: 1968
• Employees: 24,006
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 500257

Financial Performance

In fiscal year 2026, Lupin's revenue was 279.58 billion, an increase of 23.12% compared to the previous year's 227.08 billion. Earnings were 53.33 billion, an increase of 62.51%.